论文部分内容阅读
目的:对HBeAg阴性的慢性乙型病毒性肝炎应用拉米夫定与恩替卡韦治疗的效果对照进行分析。方法:资料随机选自2010年4月-2013年4月在本院诊治的慢性乙型病毒性肝炎患者78例,将患者按照随机数字表方法分为两组,每组39例,对照组给予丹参、维生素c、甘利欣等常规治疗,研究组给予拉米夫定与恩替卡韦治疗,分析患者的临床治疗效果和肝功能指标情况。结果:经不同方案的治疗后,研究组患者的总有效率为97.4%,对照组患者的总有效率为82.0%,比较差异具统计学上的意义(P<0.05);经过不同方案治疗后,研究组患者的肝功能指标变化情况低于对照组,比较差异具有统计学上的意义(P<0.05)。结论:通过应用拉米夫定与恩替卡韦药物来治疗HBeAg阴性的慢性乙型病毒性肝炎患者,能够有效改善患者的病情,提高治愈率。
Objective: To analyze the effect of lamivudine and entecavir treatment on HBeAg-negative chronic hepatitis B patients. Methods: The data were randomly selected from 78 patients with chronic hepatitis B who were diagnosed and treated in our hospital from April 2010 to April 2013. The patients were divided into two groups according to the random number table (39 patients in each group) and the control group Salvia miltiorrhiza, vitamin c, Glycyrrhizin and other conventional treatment, the study group was given lamivudine and entecavir treatment, analysis of the clinical efficacy of patients and liver function indicators. Results: After treatment with different regimens, the total effective rate of the study group was 97.4%, the total effective rate of the control group was 82.0%, the difference was statistically significant (P <0.05); after the different regimen , And the changes of liver function indexes in the study group were lower than those in the control group, the difference was statistically significant (P <0.05). Conclusion: The treatment of HBeAg-negative chronic hepatitis B patients by lamivudine and entecavir drugs can effectively improve the patient’s condition and improve the cure rate.